CNSP logo

CNS PHARMACEUTICALS INC

CNSPNASDAQ
🏆 #5083 by market capUS Equity
$5.93▲ $0.13 (+2.24%)
After hours · at close
🔔
Track CNSP
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.2%
7d▲ 0.0%
14d▲ 0.0%
30d▲ 3.0%
ytd▲ 13.4%
1y▼ 27.9%
🏦Market Cap
$9M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
52
Weak

Trading Snapshot

Day Range
$5.89 – $6.00
52-Week Range
$1.90 – $10.59
Volume
$1.80B
Avg Volume
$2.11B
Shares Outstanding
1.5M
Next Earnings
Oct 27, 2026

Fundamentals Snapshot

Annual Revenue
$901,854
Last Q Revenue
$244,040
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-23.14
Dividend Yield
—
Dilution (1yr)
+276.4%

Why Investors Own CNSP

  • ✓High-growth profile — revenue up -9.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 53% gross margin and 28% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CNSP logo

CNS PHARMACEUTICALS INC

CNSP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$16M▲ +7.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$14M▼ −19.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
443K▲ +276.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▲ +$737K YoY
StockOtter · stockotter.space

About CNS PHARMACEUTICALS INC

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100

Analyst Price Target

ⓘ
Average Target
$6.08
▲ +2.5% Upside
High Target$7.05
Low Target$5.58
Based on 27 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

CNS PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift CNSP price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

CNS PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.